Humana (HUM) News Today

Humana Inc. (NYSE: HUM) shares have increased as investors weigh expanded Medicare Advantage offerings and mostly modest upward revisions to near- and medium-term earnings estimates. However, analysts remain cautious, with Zacks Research maintaining a Hold rating and cutting some longer-term forecasts.

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.05 from $9.00 and its FY2027 forecast to $11.23 from $10.98. The firm also slightly improved its Q3 2026 and Q4 2027 estimates, suggesting some confidence in Humana’s earnings recovery. Zacks Research earnings estimates
• Positive Sentiment: Humana is expanding Medicare Advantage choices and specialized-care options for 2027 while emphasizing affordability. The offerings could support member retention and enrollment during the annual open-enrollment period. Humana 2027 Medicare Advantage plans
• Neutral Sentiment: Humana is scheduled to report third-quarter results on November 6, during Medicare Advantage open enrollment. Investors may focus on medical costs, membership trends and the financial impact of plan changes. Humana third-quarter earnings date
• Negative Sentiment: Zacks Research reduced its Q3 2028 EPS estimate to $6.58 from $6.73 and its FY2028 estimate to $29.45 from $30.30. The cuts temper the longer-term outlook, although the changes are relatively small. Humana long-term earnings estimates
• Negative Sentiment: Forecasts still call for significant seasonal losses in Q3 and Q4 2026, including estimated EPS of negative $1.13 and negative $7.75, respectively. This highlights ongoing earnings volatility and healthcare-cost risks. Humana earnings estimate report

Note: Reports about Ambea’s takeover of “Humana” and a new leader at Assistans refer to Humana AB in Sweden, not Humana Inc. (NYSE: HUM), and therefore do not directly explain the U.S. stock’s movement.